Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in C9orf72-Associated Amyotrophic Lateral Sclerosis
NCT05053035 is registered in ClinicalTrials.gov with Alector Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in C9orf72-Associated Amyotrophic Lateral Sclerosis
- Lead sponsor
- Alector Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- September 2, 2021
- Completion date
- October 28, 2022
- Enrollment
- 5 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.